Published in Am J Cardiol on December 29, 2012
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) | NCT00027352
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Inflammation as a risk factor for atrial fibrillation. Circulation (2003) 4.95
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol (2003) 2.49
RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med (2007) 1.71
High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. Clin Infect Dis (2010) 1.58
Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol (1997) 1.29
Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome. Am J Cardiol (1988) 1.25
Major and minor electrocardiographic abnormalities and risk of death from coronary heart disease, cardiovascular diseases and all causes in men and women. J Am Coll Cardiol (1988) 1.25
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. AIDS Res Hum Retroviruses (2011) 1.20
Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol (2010) 1.06
Minnesota coding and the prevalence of ECG abnormalities. Heart (2000) 0.93
C-reactive protein and electrocardiographic ST-segment depression additively predict mortality: the Strong Heart Study. J Am Coll Cardiol (2005) 0.85
Relation of electrocardiographic abnormalities to levels of serum C-reactive protein. Am J Cardiol (2003) 0.79
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature (2005) 11.12
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA (2003) 7.35
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
The prevention and treatment of missing data in clinical trials. N Engl J Med (2012) 6.92
Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J (2009) 4.90
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet (2004) 4.81
Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol (2011) 4.61
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (2010) 4.41
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet (2009) 3.80
Genome-wide association study of PR interval. Nat Genet (2010) 3.73
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol (2006) 3.51
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog (2009) 3.35
Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog (2010) 3.28
Vaccination in humans generates broad T cell cytokine responses. J Immunol (2004) 3.27
Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr (2013) 3.02
Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (2002) 2.96
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis (2011) 2.88
Collagen deposition limits immune reconstitution in the gut. J Infect Dis (2008) 2.85
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS (2008) 2.85
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis (2009) 2.78
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS (2009) 2.75
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science (2009) 2.64
Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2011) 2.64
HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med (2003) 2.62
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother (2008) 2.52
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS (2010) 2.49
Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc (2013) 2.47
CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol (2005) 2.41
Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 2.38
Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med (2010) 2.36
Genetic mapping and exome sequencing identify variants associated with five novel diseases. PLoS One (2012) 2.33
Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med (2008) 2.32
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health (2010) 2.21
A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol (2011) 2.19
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17
Whither or wither microbicides? Science (2008) 2.17
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA (2010) 2.12
Monitoring the quality of conduct of clinical trials: a survey of current practices. Clin Trials (2011) 2.08
Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation (2014) 2.05
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis (2012) 2.04
Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health (2005) 2.02
Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol (2005) 2.01
Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J (2010) 1.95
European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation (2010) 1.90
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis (2004) 1.89
Driving a decade of change: HIV/AIDS, patents and access to medicines for all. J Int AIDS Soc (2011) 1.88
Traditional risk factors as the underlying cause of racial disparities in stroke: lessons from the half-full (empty?) glass. Stroke (2011) 1.86
A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol (2010) 1.84
The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS (2015) 1.84
Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med (2003) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med (2013) 1.74
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS (2007) 1.72
Development of a framework and coding system for modifications and adaptations of evidence-based interventions. Implement Sci (2013) 1.72
Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med (2005) 1.71
Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol (2012) 1.71
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. J Infect Dis (2010) 1.69
Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières. AIDS (2003) 1.69
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 1.69
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS (2011) 1.68
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. Lancet Infect Dis (2013) 1.68
Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation (2011) 1.67
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS (2014) 1.67
Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis (2009) 1.66
Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) study. Heart Rhythm (2011) 1.64
When to start therapy for HIV infection: a swinging pendulum in search of data. Ann Intern Med (2003) 1.63
Reduction of missed appointments at an urban primary care clinic: a randomised controlled study. BMC Fam Pract (2010) 1.62